Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Germinal Centre B Cell Functions and Lymphomagenesis: Circuits Involving MYC and MicroRNAs.

Robaina MC, Mazzoccoli L, Klumb CE.

Cells. 2019 Oct 31;8(11). pii: E1365. doi: 10.3390/cells8111365. Review.

2.

miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.

Mazzoccoli L, Robaina MC, Bacchi CE, Soares Lima SC, Klumb CE.

Oncol Rep. 2019 Aug;42(2):775-784. doi: 10.3892/or.2019.7183. Epub 2019 Jun 3.

PMID:
31173259
3.

IKZF1 deletion and co-occurrence with other aberrations in a child with chronic myeloid leukemia progressing to acute lymphoblastic leukemia.

Klumb CE, Barbosa TDC, Nestal de Moraes G, Schramm MT, Emerenciano M, Maia RC.

Pediatr Blood Cancer. 2019 Apr;66(4):e27570. doi: 10.1002/pbc.27570. Epub 2018 Dec 4.

PMID:
30511400
4.

MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.

Mazzoccoli L, Robaina MC, Apa AG, Bonamino M, Pinto LW, Queiroga E, Bacchi CE, Klumb CE.

J Cancer Res Clin Oncol. 2018 Mar;144(3):483-497. doi: 10.1007/s00432-017-2575-3. Epub 2018 Jan 9.

PMID:
29318382
5.

miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis.

Robaina MC, Faccion RS, Mazzoccoli L, Rezende LM, Queiroga E, Bacchi CE, Thomas-Tikhonenko A, Klumb CE.

Ann Hematol. 2016 May;95(6):881-91. doi: 10.1007/s00277-016-2653-7. Epub 2016 Apr 5.

PMID:
27044389
6.

Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.

Ferreira AC, de-Freitas-Junior JC, Morgado-Díaz JA, Ridley AJ, Klumb CE.

J Leukoc Biol. 2016 Apr;99(4):569-78. doi: 10.1189/jlb.2A0415-162R. Epub 2015 Nov 11.

PMID:
26561567
7.

NFAT2 Isoforms Differentially Regulate Gene Expression, Cell Death, and Transformation through Alternative N-Terminal Domains.

Lucena PI, Faget DV, Pachulec E, Robaina MC, Klumb CE, Robbs BK, Viola JP.

Mol Cell Biol. 2015 Oct 19;36(1):119-31. doi: 10.1128/MCB.00501-15. Print 2016 Jan 1.

8.

An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation.

Maia RC, Bonamino MH, Robaina MC, Amaral N, Bonecker S, Zalcberg IR, Klumb CE.

Blood Cells Mol Dis. 2015 Dec;55(4):347-50. doi: 10.1016/j.bcmd.2015.07.013. Epub 2015 Jul 21.

PMID:
26460258
9.

Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.

Nakamura KD, Tilli TM, Wanderley JL, Palumbo A Jr, Mattos RM, Ferreira AC, Klumb CE, Nasciutti LE, Gimba ER.

Tumour Biol. 2016 Feb;37(2):2655-63. doi: 10.1007/s13277-015-4095-6. Epub 2015 Sep 24.

PMID:
26404131
10.

Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis.

Robaina MC, Mazzoccoli L, Arruda VO, Reis FR, Apa AG, de Rezende LM, Klumb CE.

Exp Mol Pathol. 2015 Apr;98(2):200-7. doi: 10.1016/j.yexmp.2015.03.006. Epub 2015 Mar 4.

PMID:
25746661
11.

Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications.

Robaina MC, Faccion RS, Arruda VO, de Rezende LM, Vasconcelos GM, Apa AG, Bacchi CE, Klumb CE.

Leuk Res. 2015 Feb;39(2):248-56. doi: 10.1016/j.leukres.2014.11.023. Epub 2014 Dec 9.

PMID:
25542698
12.

Rosai-Dorfman disease: a report of eight cases in a tertiary care center and a review of the literature.

Maia RC, de Meis E, Romano S, Dobbin JA, Klumb CE.

Braz J Med Biol Res. 2015 Jan;48(1):6-12. Epub 2014 Oct 10.

13.

Langerhans cell histiocytosis: differences and similarities in long-term outcome of paediatric and adult patients at a single institutional centre.

Maia RC, de Rezende LM, Robaina M, Apa A, Klumb CE.

Hematology. 2015 Mar;20(2):83-92. doi: 10.1179/1607845414Y.0000000173. Epub 2014 May 29.

PMID:
24875166
14.

Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.

Ferreira AC, Robaina MC, Rezende LM, Severino P, Klumb CE.

Ann Hematol. 2014 Jun;93(6):983-93. doi: 10.1007/s00277-014-2021-4. Epub 2014 Feb 28.

PMID:
24577510
15.

A step towards the cure of Burkitt's lymphoma in developing countries.

Klumb CE.

Rev Bras Hematol Hemoter. 2012;34(5):332-3. doi: 10.5581/1516-8484.20120087. No abstract available.

16.

Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma.

Minnicelli C, Barros MH, Klumb CE, Romano SO, Zalcberg IR, Hassan R.

PLoS One. 2012;7(9):e46005. doi: 10.1371/journal.pone.0046005. Epub 2012 Sep 27.

17.

Lymphoma subtype incidence rates in children and adolescents: first report from Brazil.

Ferreira JM, Klumb CE, de Souza Reis R, de Oliveira Santos M, Oliveira JF, de Camargo B, Pombo-de-Oliveira MS.

Cancer Epidemiol. 2012 Aug;36(4):e221-6. doi: 10.1016/j.canep.2012.03.006. Epub 2012 May 1.

18.

Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.

Dos Santos Ferreira AC, Fernandes RA, Kwee JK, Klumb CE.

J Cancer Res Clin Oncol. 2012 Feb;138(2):317-25. doi: 10.1007/s00432-011-1093-y. Epub 2011 Dec 1.

PMID:
22131152
19.

Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.

Vasconcelos FC, Silva KL, Souza PS, Silva LF, Moellmann-Coelho A, Klumb CE, Maia RC.

Cytometry B Clin Cytom. 2011 May;80(3):158-66. doi: 10.1002/cyto.b.20580. Epub 2010 Dec 2.

20.

Pediatric lymphomas in Brazil.

Gualco G, Klumb CE, Barber GN, Weiss LM, Bacchi CE.

Clinics (Sao Paulo). 2010;65(12):1267-77.

21.

Circulating cell-free and Epstein-Barr virus DNA in pediatric B-non-Hodgkin lymphomas.

Machado AS, Da Silva Robaina MC, Magalhães De Rezende LM, Apa AG, Amoêdo ND, Bacchi CE, Klumb CE.

Leuk Lymphoma. 2010 Jun;51(6):1020-7. doi: 10.3109/10428191003746331.

PMID:
20470219
22.

p53 flow cytometry evaluation in leukemias: correlation to factors affecting clinical outcome.

Cavalcanti GB Jr, Scheiner MA, Simões Magluta EP, Vasconcelos FC, Klumb CE, Maia RC.

Cytometry B Clin Cytom. 2010 Jul;78(4):253-9. doi: 10.1002/cyto.b.20514.

23.

Insights into apoptosis mechanisms induced by DNA-damaging agents in Burkitt's lymphoma cells.

Simões Magluta EP, Vasconcelos FC, Maia RC, Klumb CE.

Cancer Invest. 2009 Oct;27(8):830-5. doi: 10.1080/07357900902849624.

PMID:
19557576
24.

Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma.

Gualco G, Queiroga EM, Weiss LM, Klumb CE, Harrington WJ Jr, Bacchi CE.

Hum Pathol. 2009 Apr;40(4):565-71. doi: 10.1016/j.humpath.2008.07.021. Epub 2009 Jan 13.

25.

Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features.

Queiroga EM, Gualco G, Weiss LM, Dittmer DP, Araujo I, Klumb CE, Harrington WJ Jr, Bacchi CE.

Am J Clin Pathol. 2008 Dec;130(6):946-56. doi: 10.1309/AJCP64YOHAWLUMPK.

26.

Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation.

Kwee JK, Luque DG, Ferreira AC, Vasconcelos FC, Silva KL, Klumb CE, Maia RC.

Anticancer Drugs. 2008 Nov;19(10):975-81. doi: 10.1097/CAD.0b013e3283140c6f.

PMID:
18827562
27.

Plasma Epstein-Barr viral load predicting response after chemotherapy for post-transplant lymphoproliferative disease.

Machado AS, Apa AG, Magalhães de Rezende LM, Amoêdo ND, Rumjanek FD, Bacchi CE, Klumb CE.

Clin Exp Med. 2008 Jun;8(2):129-32. doi: 10.1007/s10238-008-0168-9. Epub 2008 Jul 11.

PMID:
18618224
28.

Second Epstein-Barr virus-associated Burkitt's lymphoma of the CNS in a child with progressive renal failure.

Hassan R, Stefanoff CG, Felisbino F, Barros MH, Zalcberg IR, Klumb CE, Bigni RS, Seuánez HN.

J Clin Oncol. 2008 Jun 20;26(18):3085-7. doi: 10.1200/JCO.2007.15.1431. No abstract available.

PMID:
18565896
29.

Clinical and demographic characteristics of Epstein-Barr virus-associated childhood Burkitt's lymphoma in Southeastern Brazil: epidemiological insights from an intermediate risk region.

Hassan R, Klumb CE, Felisbino FE, Guiretti DM, White LR, Stefanoff CG, Barros MH, Seuánez HN, Zalcberg IR.

Haematologica. 2008 May;93(5):780-3. doi: 10.3324/haematol.12424. Epub 2008 Mar 26.

30.

Burkitt lymphoma/leukaemia transformed from a precursor B cell: clinical and molecular aspects.

Hassan R, Felisbino F, Stefanoff CG, Pires V, Klumb CE, Dobbin J, Seuánez HN, Renault IZ.

Eur J Haematol. 2008 Mar;80(3):265-70. Epub 2007 Nov 15.

PMID:
18005389
31.

Long-term outcome of children and adolescents treated with the COPP-ABV hybrid protocol for Hodgkin's disease: balance of risks.

Klumb CE, Carriço MK, de Rezende LM, Byington R, Bordallo MA, Bigni RS, Apa AG, Dobbin JA.

Clin Oncol (R Coll Radiol). 2007 Oct;19(8):628-9. Epub 2007 Jul 26. No abstract available.

PMID:
17662581
32.

Retinoblastoma-related geneRb2/p130 are rarely mutated in Burkitt's lymphoma from Brazil.

Klumb CE, Magluta EP, Rezende LM, Apa AG, Alonso JF, Maia RC.

Am J Hematol. 2007 Mar;82(3):238-9.

33.

Epstein-Barr virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma.

Hassan R, White LR, Stefanoff CG, de Oliveira DE, Felisbino FE, Klumb CE, Bacchi CE, Seuánez HN, Zalcberg IR.

Diagn Pathol. 2006 Aug 7;1:17.

34.

Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.

Cavalcanti GB Jr, Vasconcelos FC, Pinto de Faria G, Scheiner MA, de Almeida Dobbin J, Klumb CE, Maia RC.

Cytometry B Clin Cytom. 2004 Sep;61(1):1-8.

35.

p53 protein expression does not correlate with EBV status in childhood B non-Hodgkin lymphomas.

Klumb CE, Hassan R, Zalcberg IR, Resende LM, Carriço MK, Maia RC.

Pediatr Blood Cancer. 2004 Aug;43(2):115-9.

PMID:
15236276
36.

Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.

Klumb CE, Schramm MT, De Resende LM, Carriço MK, Coelho AM, de Meis E, Ferreira RM, Maia RC, Dobbin Jde A.

J Pediatr Hematol Oncol. 2004 Jul;26(7):462-8.

PMID:
15218425
37.

Geographic variation in Epstein-Barr virus-associated Burkitt's lymphoma in children from Brazil.

Klumb CE, Hassan R, De Oliveira DE, De Resende LM, Carriço MK, De Almeida Dobbin J, Pombo-De-Oliveira MS, Bacchi CE, Maia RC.

Int J Cancer. 2004 Jan 1;108(1):66-70.

38.

DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications.

Klumb CE, Furtado DR, de Resende LM, Carriço MK, Coelho AM, de Meis E, Maia RC, Rumjanek FD.

Eur J Haematol. 2003 Aug;71(2):81-90.

PMID:
12890146
39.

Burkitt-like lymphoma in an infant: a case report.

Klumb CE, de Resende LM, Stefanoff CG, Vicuña CH, Renault IZ, Maia RC.

Rev Hosp Clin Fac Med Sao Paulo. 2003 Jan-Feb;58(1):33-6. Epub 2003 Apr 30.

PMID:
12754588
40.

p53 gene analysis in childhood B non-Hodgkin's lymphoma.

Klumb CE, de Resende LM, Tajara EH, Bertelli EC, Rumjanek VM, Maia RC.

Sao Paulo Med J. 2001 Nov 1;119(6):212-5.

41.

Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide.

Maia RC, Carriço MK, Klumb CE, Noronha H, Coelho AM, Vasconcelos FC, Ruimanek VM.

J Exp Clin Cancer Res. 1997 Dec;16(4):419-24.

PMID:
9505216

Supplemental Content

Loading ...
Support Center